RxDoctor Payments Data

Kathleen Filiaggi, MD

Internal Medicine · Key West, FLNPI 1720070295

Payments from drug & device makers

$1,009in general payments, 2019–2025

Across 13 payments — averaging $77.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$556
  • Ultragenyx Pharmaceutical Inc.$125
  • Astellas Pharma US Inc$125
  • Boehringer Ingelheim$120
  • Exact Sciences$40
  • AstraZeneca$15
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$1,009100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,009 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$100,501
Medicare patients
342
Services billed
1,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$41,106
EliquisApixaban32$38,447
MounjaroTirzepatide18$18,280
Breo ElliptaFluticasone/Vilanterol12$5,184
Atorvastatin Calcium171$1,257
Losartan Potassium138$1,225
Rosuvastatin Calcium85$1,158
Gabapentin72$1,156
Pantoprazole Sodium67$1,086
Estradiol13$1,050
Levothyroxine Sodium87$820
Omeprazole43$640
Tamsulosin Hcl34$626
Metoprolol Succinate49$623
SynthroidLevothyroxine Sodium12$622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$41,10635 claims
Lilly USA, LLCMounjaro$15$18,28018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Key West

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →